Cargando…

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia

Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kushitani, Kei, Amatya, Vishwa Jeet, Mawas, Amany Sayed, Suzuki, Rui, Miyata, Yoshihiro, Okada, Morihito, Inai, Kouki, Kishimoto, Takumi, Takeshima, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796295/
https://www.ncbi.nlm.nih.gov/pubmed/29467873
http://dx.doi.org/10.3892/ol.2018.7765
_version_ 1783297478559268864
author Kushitani, Kei
Amatya, Vishwa Jeet
Mawas, Amany Sayed
Suzuki, Rui
Miyata, Yoshihiro
Okada, Morihito
Inai, Kouki
Kishimoto, Takumi
Takeshima, Yukio
author_facet Kushitani, Kei
Amatya, Vishwa Jeet
Mawas, Amany Sayed
Suzuki, Rui
Miyata, Yoshihiro
Okada, Morihito
Inai, Kouki
Kishimoto, Takumi
Takeshima, Yukio
author_sort Kushitani, Kei
collection PubMed
description Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using immunohistochemistry. Formalin-fixed, paraffin-embedded specimens from 78 cases of EM and 80 cases of RMH were immunohistochemically examined for Survivin, BAP1, and Ki-67. In addition, receiver operating characteristic curve analyses were performed to establish the cut-off values for Survivin and Ki-67 labelling indices. Survivin (cut-off value: 5%) had 67.7% sensitivity and 100% specificity, while Ki-67 (cut-off value: 10%) had 85.1% sensitivity and 87.5% specificity, and BAP1 had 66.2% sensitivity and 100% specificity for the differentiation of EM from RMH. Among the combinations of two markers, the combination of Survivin and BAP1 (Survivin-positive and/or BAP1-loss finding) had the highest diagnostic accuracy (sensitivity: 89.8%; specificity: 100%; accuracy: 95.3%). We recommend using the combination of Survivin and BAP1 to distinguish EM from RMH.
format Online
Article
Text
id pubmed-5796295
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-57962952018-02-21 Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia Kushitani, Kei Amatya, Vishwa Jeet Mawas, Amany Sayed Suzuki, Rui Miyata, Yoshihiro Okada, Morihito Inai, Kouki Kishimoto, Takumi Takeshima, Yukio Oncol Lett Articles Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using immunohistochemistry. Formalin-fixed, paraffin-embedded specimens from 78 cases of EM and 80 cases of RMH were immunohistochemically examined for Survivin, BAP1, and Ki-67. In addition, receiver operating characteristic curve analyses were performed to establish the cut-off values for Survivin and Ki-67 labelling indices. Survivin (cut-off value: 5%) had 67.7% sensitivity and 100% specificity, while Ki-67 (cut-off value: 10%) had 85.1% sensitivity and 87.5% specificity, and BAP1 had 66.2% sensitivity and 100% specificity for the differentiation of EM from RMH. Among the combinations of two markers, the combination of Survivin and BAP1 (Survivin-positive and/or BAP1-loss finding) had the highest diagnostic accuracy (sensitivity: 89.8%; specificity: 100%; accuracy: 95.3%). We recommend using the combination of Survivin and BAP1 to distinguish EM from RMH. D.A. Spandidos 2018-03 2018-01-10 /pmc/articles/PMC5796295/ /pubmed/29467873 http://dx.doi.org/10.3892/ol.2018.7765 Text en Copyright: © Kushitani et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kushitani, Kei
Amatya, Vishwa Jeet
Mawas, Amany Sayed
Suzuki, Rui
Miyata, Yoshihiro
Okada, Morihito
Inai, Kouki
Kishimoto, Takumi
Takeshima, Yukio
Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
title Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
title_full Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
title_fullStr Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
title_full_unstemmed Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
title_short Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
title_sort utility of survivin, bap1, and ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796295/
https://www.ncbi.nlm.nih.gov/pubmed/29467873
http://dx.doi.org/10.3892/ol.2018.7765
work_keys_str_mv AT kushitanikei utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT amatyavishwajeet utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT mawasamanysayed utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT suzukirui utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT miyatayoshihiro utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT okadamorihito utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT inaikouki utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT kishimototakumi utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia
AT takeshimayukio utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia